News Archive - Clexio

23 May 2024

Clexio announces 50% enrollment milestone reached, in CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica

15 April 2024

Clexio Biosciences expands its protection of CLE100 with the issuance of a third US method of use patent and the allowance of an additional three US patents

10 April 2024

Clexio initiates enrolment in SOLEO Study, a Phase 2 study assessing the safety and efficacy of CLE-100 as an adjunctive treatment in subjects with Major Depressive Disorder

4 April 2024

Clexio presents CLEO trial results at Oxford Conference on Ketamine and Related Compounds

15 February 2024

Clexio Biosciences receives second US method of use patent for CLE400

5 February 2024

Clexio initiates Phase 2 Proof of Concept Study to assess efficacy and Safety of CLE-400 gel for the treatment of Notalgia Paresthetica

15 January 2024

Clexio Biosciences receives second US method of use patent for CLE100

10 January 2024

Clexio publication in ONdrugDelivery : Taking a drug to First-In-Human trials in a bespoke device for targeted intranasal delivery

15 November 2023

Clexio presents CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus at the 7th Annual Dermatology Drug Development Summit

10 November 2023

Clexio receives FDA IND clearance for a Phase 2 POC study evaluating CLE-400, a novel topical therapy for localized chronic pruritus. Final protocol submitted.

15 May 2023

Clexio presents results of CLEO study “A Phase 2 Randomized Controlled Adjunctive Treatment Trial With CLE-100 Esketamine Tablet in Patients with Major Depressive Disorder (MDD) with Inadequate Response to Antidepressants” at American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2023)

13 January 2023

Clexio Biosciences expands its proprietary OLAR platform with issuance of ninth US patent

15 February 2022

Successful Completion of Phase 1 Multiple Ascending Dose Clinical Trial of the CLE-400 topical gel

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Latest News

Clexio announces 50% enrollment milestone reached, in CLE-400 Phase 2 proof-of-concept study, in subjects suffering from chronic pruritus associated with Notalgia Paresthetica

Clexio Biosciences expands its protection of CLE100 with the issuance of a third US method of use patent and the allowance of an additional three US patents

Clexio initiates enrolment in SOLEO Study, a Phase 2 study assessing the safety and efficacy of CLE-100 as an adjunctive treatment in subjects with Major Depressive Disorder

Clexio presents CLEO trial results at Oxford Conference on Ketamine and Related Compounds

Clexio Biosciences receives second US method of use patent for CLE400

Clexio initiates Phase 2 Proof of Concept Study to assess efficacy and Safety of CLE-400 gel for the treatment of Notalgia Paresthetica

Clexio Biosciences receives second US method of use patent for CLE100

Clexio publication in ONdrugDelivery : Taking a drug to First-In-Human trials in a bespoke device for targeted intranasal delivery

Clexio presents CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus at the 7th Annual Dermatology Drug Development Summit

Clexio receives FDA IND clearance for a Phase 2 POC study evaluating CLE-400, a novel topical therapy for localized chronic pruritus. Final protocol submitted.

Clexio Biosciences expands its proprietary OLAR platform with issuance of ninth US patent

Successful Completion of Phase 1 Multiple Ascending Dose Clinical Trial of the CLE-400 topical gel

Address

Contact